SecBot SecBot
SECBOTREPLAY Home › Report › LYEL

LYEL · Lyell Immunopharma closed an additional $50 million tranche of its…

Lyell Immunopharma, Inc · PRESS-RELEASE filed Mar 9, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 9, 2026 at 08:00 ET

Lyell Immunopharma closed an additional $50 million tranche of its private placement, bringing total proceeds to $100 million, following a clinical milestone in its ronde-cel PiNACLE trial for relapsed/refractory large B-cell lymphoma. The company also appointed Smital Shah as Chief Financial and Business Officer to lead financial strategy amid this capital raise.

  • Lyell closed an additional $50 million tranche of a $100 million private placement after achieving a clinical milestone in the ronde-cel PiNACLE trial.
  • Total gross proceeds from the private placement are now $100 million, priced at $25.61 per share.
  • Cash runway is expected to extend into Q2 2027.
  • Smital Shah was appointed Chief Financial and Business Officer, effective March 9, 2026, bringing extensive biopharma finance and strategy experience.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access